Assessment of 2021/22 influenza epidemic scenarios in Italy during SARS-CoV-2 outbreak.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2023
Historique:
received: 22 12 2022
accepted: 22 02 2023
entrez: 9 3 2023
pubmed: 10 3 2023
medline: 14 3 2023
Statut: epublish

Résumé

Global mitigation strategies to tackle the threat posed by SARS-CoV-2 have produced a significant decrease of the severity of 2020/21 seasonal influenza, which might result in a reduced population natural immunity for the upcoming 2021/22 influenza season. To predict the spread of influenza virus in Italy and the impact of prevention and control measures, we present an age-structured Susceptible-Exposed-Infectious-Removed (SEIR) model including the role of social mixing patterns and the impact of age-stratified vaccination strategies and Non-Pharmaceutical Interventions (NPIs) such as school closures, partial lockdown, as well as the adoption of personal protective equipment and the practice of hand hygiene. We find that vaccination campaigns with standard coverage would produce a remarkable mitigation of the spread of the disease in moderate influenza seasons, making the adoption of NPIs unnecessary. However, in case of severe seasonal epidemics, a standard vaccination coverage would not be sufficiently effective in fighting the epidemic, thus implying that a combination with the adoption of NPIs is necessary to contain the disease. Alternatively, our results show that the enhancement of the vaccination coverage would reduce the need to adopt NPIs, thus limiting the economic and social impacts that NPIs might produce. Our results highlight the need to respond to the influenza epidemic by strengthening the vaccination coverage.

Identifiants

pubmed: 36893137
doi: 10.1371/journal.pone.0282782
pii: PONE-D-22-35084
pmc: PMC9997945
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0282782

Informations de copyright

Copyright: © 2023 Chironna et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

PLoS One. 2012;7(1):e29744
pubmed: 22295066
PLoS One. 2017 Jan 11;12(1):e0169801
pubmed: 28076411
Euro Surveill. 2016 Apr 21;21(16):
pubmed: 27124420
Fam Pract. 2001 Dec;18(6):629-34
pubmed: 11739352
Lancet Public Health. 2020 May;5(5):e279-e288
pubmed: 32311320
F1000Res. 2017 Aug 29;6:1584
pubmed: 29552335
PLoS One. 2021 Jun 15;16(6):e0252271
pubmed: 34129608
Proc Natl Acad Sci U S A. 2021 Jan 26;118(4):
pubmed: 33431650
PLoS Comput Biol. 2021 Jul 26;17(7):e1009098
pubmed: 34310590
J Infect. 2017 Nov;75(5):381-394
pubmed: 28935236
PLoS Comput Biol. 2012;8(9):e1002673
pubmed: 23028275
Results Phys. 2021 Sep;28:104629
pubmed: 34367890
PLoS Comput Biol. 2021 Jul 26;17(7):e1009149
pubmed: 34310589
J Clin Med. 2020 Feb 07;9(2):
pubmed: 32046137
Infect Dis Model. 2020 Feb 11;5:248-255
pubmed: 32099934
J Infect. 2011 May;62(5):379-87
pubmed: 21414357
JAMA. 2020 Oct 6;324(13):1342-1343
pubmed: 32797145
Vaccines (Basel). 2021 Mar 18;9(3):
pubmed: 33803755
Emerg Infect Dis. 2020 Aug;26(8):1933-1935
pubmed: 32339092
Epidemiol Infect. 2008 Dec;136(12):1650-7
pubmed: 18272019
J Pediatr. 2021 Jan;228:87-93.e2
pubmed: 32771480
J Transl Med. 2017 Jun 1;15(1):124
pubmed: 28569196
Euro Surveill. 2015 Feb 19;20(7):29-38
pubmed: 25719965
Int J Health Policy Manag. 2021 Jun 09;:
pubmed: 34273920
Int J Infect Dis. 2019 Nov;88:127-134
pubmed: 31401203
Eur J Clin Microbiol Infect Dis. 2000 Nov;19(11):834-42
pubmed: 11152308
Nat Commun. 2021 May 31;12(1):3249
pubmed: 34059675
Science. 2005 Aug 12;309(5737):1083-7
pubmed: 16079251
Open Forum Infect Dis. 2021 Dec 23;9(1):ofab607
pubmed: 35024374
Nature. 2005 Sep 8;437(7056):209-14
pubmed: 16079797
Bull Math Biol. 1991;53(1-2):57-87
pubmed: 2059742
Hum Vaccin Immunother. 2022 Dec 31;18(1):1978795
pubmed: 34613881
Stat Med. 1988 Nov;7(11):1147-55
pubmed: 3201040

Auteurs

Maria Chironna (M)

Department of interdisciplinary Medicine, University of Bari, Aldo Moro Policlinico, Bari, Italy.

Jean Marie Franzini (JM)

BIP Life Sciences, BIP spa, Milan, Italy.

Giancarlo Icardi (G)

Department of Health's Science (DiSSal), University of Genoa, Genoa, Italy.
Hygiene Unit, San Martino Policlinico Hospital-IRCCS for Oncology and Neurosciences, Genoa, Italy.

Daniela Loconsole (D)

Department of interdisciplinary Medicine, University of Bari, Aldo Moro Policlinico, Bari, Italy.

Elena Pariani (E)

Department of Biomedical Sciences for Health, University of Milan, Milan, Italy.

Stefano Pastore (S)

BIP Life Sciences, BIP spa, Milan, Italy.

Marco Volpe (M)

BIP Life Sciences, BIP spa, Milan, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH